Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison

• Published in: Journal of the American Society of Hypertension Vol. 9; no. 2; p. 86
• Main Authors: Andersen, Louise Bjørkholt, Frederiksen-Møller, Britta, Work Havelund, Kathrine, Dechend, Ralf, Jørgensen, Jan Stener, Jensen, Boye L, Nielsen, Jan, Lykkedegn, Sine, Barington, Torben, Christesen, Henrik Thybo
• Format: Journal Article
• Language: English
• Published: United States 01-02-2015
• Subjects: Adult; Biomarkers - blood; Early Diagnosis; Enzyme-Linked Immunosorbent Assay; Female; Gestational Age; Humans; Infant, Newborn; Luminescent Measurements - methods; Male; Placenta Growth Factor; Pre-Eclampsia - blood; Pre-Eclampsia - diagnosis; Pregnancy; Pregnancy Proteins - blood; Pregnancy Trimester, Second - blood; Pregnancy Trimester, Third - blood; Retrospective Studies; Vascular Endothelial Growth Factor Receptor-1 - blood; Hypertension; obesity; HELLP syndrome; pregnancy
• DOI: 10.1016/j.jash.2014.11.008
• EISSN: 1878-7436

The angiogenic factor ratio soluble Fms-kinase 1 (sFlt-1)/placental growth factor (PlGF) is a novel diagnostic tool for preeclampsia. We compared the efficacy of the KRYPTOR (BRAHMS) automated assays for sFlt-1 and PlGF with the Elecsys (Roche) assays in a routine clinical setting. Preeclamptic women (n = 39) were included shortly after the time of diagnosis. Normotensive control pregnancies were matched by gestational age (n = 76). The KRYPTOR assays performed comparably or superior to Elecsys (sFlt-1/PlGF area under the curve 0.746 versus 0.735; P = .09; for non-obese 0.820 versus 0.805, P = .047). For early-onset preeclampsia, KRYPTOR area under the curve increased to 0.929 with a 100% specificity for preeclampsia at cut-off 85 and an 88.9% sensitivity for preeclampsia at cut-off 33. For women with preeclampsia and preterm delivery or Hemolysis, Elevated Liver enzymes, Low Platelet count (HELLP) syndrome, the KRYPTOR sFlt-1/PlGF ratio was manifold increased (P < .01). The sFlt-1/PlGF ratio proved especially useful in early-onset preeclampsia, preeclampsia with preterm delivery or HELLP, and among non-obese women.